메뉴 건너뛰기




Volumn 57, Issue 3, 2011, Pages 317-324

The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data

Author keywords

clopidogrel; gatekeeping analysis; pharmacodynamics; prasugrel

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL;

EID: 79952817340     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182073dfb     Document Type: Article
Times cited : (17)

References (30)
  • 1
  • 2
    • 75749102996 scopus 로고    scopus 로고
    • Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans
    • Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50:126-142.
    • (2010) J Clin Pharmacol. , vol.50 , pp. 126-142
    • Farid, N.A.1    Kurihara, A.2    Wrighton, S.A.3
  • 3
    • 18044378766 scopus 로고    scopus 로고
    • 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis
    • DOI 10.1055/s-2005-869523
    • 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005;31:174-183. (Pubitemid 40605192)
    • (2005) Seminars in Thrombosis and Hemostasis , vol.31 , Issue.2 , pp. 174-183
    • Savi, P.1    Herbert, J.-M.2
  • 4
    • 70450199115 scopus 로고    scopus 로고
    • Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update)
    • 2009 ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    • Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol. 2009;54:2205-2241.
    • (2009) JAm Coll Cardiol. , vol.54 , pp. 2205-2241
    • Kushner, F.G.1    Hand, M.2    Smith Jr., S.C.3
  • 5
    • 0034762075 scopus 로고    scopus 로고
    • Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement [1]
    • Muller I, Seyfarth M, Rüdiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001;85:92-93. (Pubitemid 32973418)
    • (2001) Heart , vol.85 , Issue.1 , pp. 92-93
    • Muller, I.1    Seyfarth, M.2    Rudiger, S.3    Wolf, B.4    Pogatsa-Murray, G.5    Schomig, A.6    Gawaz, M.7
  • 6
    • 18144371221 scopus 로고    scopus 로고
    • The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting
    • DOI 10.1016/j.jacc.2005.01.030
    • Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. JAm Coll Cardiol. 2005;45:1392-1396. (Pubitemid 40615608)
    • (2005) Journal of the American College of Cardiology , vol.45 , Issue.9 , pp. 1392-1396
    • Gurbel, P.A.1    Bliden, K.P.2    Hayes, K.M.3    Yoho, J.A.4    Herzog, W.R.5    Tantry, U.S.6
  • 7
    • 27744516843 scopus 로고    scopus 로고
    • Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) trial
    • DOI 10.1161/CIRCULATIONAHA.105.559088
    • von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112: 2946-2950. (Pubitemid 41612296)
    • (2005) Circulation , vol.112 , Issue.19 , pp. 2946-2950
    • Von Beckerath, N.1    Taubert, D.2    Pogatsa-Murray, G.3    Schomig, E.4    Kastrati, A.5    Schomig, A.6
  • 8
    • 19644372173 scopus 로고    scopus 로고
    • Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention
    • DOI 10.1161/01.CIR.0000160869.75810.98
    • Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose ofclopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564. (Pubitemid 40740853)
    • (2005) Circulation , vol.111 , Issue.20 , pp. 2560-2564
    • Hochholzer, W.1    Trenk, D.2    Frundi, D.3    Blanke, P.4    Fischer, B.5    Andris, K.6    Bestehorn, H.-P.7    Buttner, H.J.8    Neumann, F.-J.9
  • 9
    • 33747874088 scopus 로고    scopus 로고
    • A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial
    • DOI 10.1016/j.jacc.2006.04.090, PII S0735109706016421
    • Montalescot G, Sideris G, Meuleman C, et al; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. JAm Coll Cardiol. 2006. 48. 931-938. (Pubitemid 44292463)
    • (2006) Journal of the American College of Cardiology , vol.48 , Issue.5 , pp. 931-938
    • Montalescot, G.1    Sideris, G.2    Meuleman, C.3    Bal-dit-Sollier, C.4    Lellouche, N.5    Steg, Ph.G.6    Slama, M.7    Milleron, O.8    Collet, J.-P.9    Henry, P.10    Beygui, F.11    Drouet, L.12
  • 10
    • 57149119456 scopus 로고    scopus 로고
    • Randomized trial comparing 600-with 300-mg loading dose ofclopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial
    • Yong G, Rankin J, Ferguson L, et al. Randomized trial comparing 600-with 300-mg loading dose ofclopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. Am Heart J. 2009;157:60.e1-60.e9.
    • (2009) Am Heart J. , vol.157
    • Yong, G.1    Rankin, J.2    Ferguson, L.3
  • 11
    • 33646732608 scopus 로고    scopus 로고
    • Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
    • Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
    • (2006) Eur Heart J. , vol.27 , pp. 1166-1173
    • Jernberg, T.1    Payne, C.D.2    Winters, K.J.3
  • 14
    • 38949144302 scopus 로고    scopus 로고
    • Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
    • DOI 10.1080/09537100801891640, PII 793332448
    • Payne CD, Li YG, Brandt JT, et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets. 2008;19:275-281. (Pubitemid 351874155)
    • (2008) Platelets , vol.19 , Issue.4 , pp. 275-281
    • Payne, C.D.1    Li, Y.G.2    Brandt, J.T.3    Jakubowski, J.A.4    Small, D.S.5    Farid, N.A.6    Salazar, D.E.7    Winters, K.J.8
  • 15
    • 37849002889 scopus 로고    scopus 로고
    • 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    • 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30.
    • (2008) Eur Heart J. , vol.29 , pp. 21-30
    • Wallentin, L.1    Varenhorst, C.2    James, S.3
  • 17
    • 33845451677 scopus 로고    scopus 로고
    • A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation
    • Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153: 66-16.
    • (2007) Am Heart J. , vol.153 , pp. 66-16
    • Brandt, J.T.1    Payne, C.D.2    Wiviott, S.D.3
  • 18
    • 57149084688 scopus 로고    scopus 로고
    • Effect of atorvastatin on the pharmacokinetics and pharmacodynamics ofprasugrel and clopidogrel in healthy subjects
    • Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics ofprasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28:1483-1494.
    • (2008) Pharmacotherapy. , vol.28 , pp. 1483-1494
    • Farid, N.A.1    Small, D.S.2    Payne, C.D.3
  • 20
    • 50249184573 scopus 로고    scopus 로고
    • Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
    • Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24:2251-2257.
    • (2008) Curr Med Res Opin. , vol.24 , pp. 2251-2257
    • Small, D.S.1    Farid, N.A.2    Li, Y.G.3
  • 21
    • 78650293730 scopus 로고    scopus 로고
    • Comparison ofprasugrel with clopidogrel on platelet function in coronary artery disease patients with type 2 diabetes mellitus\Third Optimizing Anti-Platelet Therapy in Diabetes Mellit US (OPTIMUS-3)
    • abstract 4946
    • Angiolillo DJ, Badimon J, Saucedo JF, et al. Comparison ofprasugrel with clopidogrel on platelet function in coronary artery disease patients with type 2 diabetes mellitus\Third Optimizing Anti-Platelet Therapy in Diabetes Mellit US (OPTIMUS-3). Circulation. 2009;120:S1027; abstract 4946.
    • (2009) Circulation. , vol.120
    • Angiolillo, D.J.1    Badimon, J.2    Saucedo, J.F.3
  • 22
    • 79953817883 scopus 로고    scopus 로고
    • Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent
    • April 2. [Epub ahead of print]
    • Small DS, Li YG, Ernest CS, et al. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. J Clin Pharmacol. 2010, April 2. [Epub ahead of print].
    • J Clin Pharmacol. , vol.2010
    • Small, D.S.1    Li, Y.G.2    Ernest, C.S.3
  • 25
    • 79953814864 scopus 로고    scopus 로고
    • Available at Accessed May 11, 2010
    • Effient [package insert]. Available at: http://pi.lilly.com/us/effient. pdf. Accessed May 11, 2010.
    • Effient [Package Insert]
  • 27
    • 77950508416 scopus 로고    scopus 로고
    • Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study
    • Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188-1199.
    • (2010) Circulation. , vol.121 , pp. 1188-1199
    • Gurbel, P.A.1    Bliden, K.P.2    Butler, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.